Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

Inclusion Criteria: * Non-smoker for at least 12 months prior to screening for the study * BMI ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive) * Medically healthy without clinically significant abnormalities as assessed by the Investigator based on screening medical history, physical examination, vital signs, 12-lead ECG, hematology, biochemistry, coagulation, and urinalysis * Forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value at screening * Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food from 48 hours prior to study drug administration until discharge from the clinical unit * If male, must agree to use a condom and have a non-pregnant female partner of childbearing potential agree to use a highly effective method of contraception * If female, must be of non-childbearing potential or, if female of childbearing potential, a willingness to abstain from sexual activity or agree to use a high effective method of contraception that could lead to pregnancy * Other inclusion criteria per protocol Exclusion Criteria: * History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, vascular or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be clinically relevant * Recent history (within 6 months) of known or suspected Clostridium difficile infection * History of seizure disorders * Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1) * Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV Ab) * Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening or prior to first dosing * Presence of the following symptoms at screening or within 28 days prior to screening or check-in (Day -1): 1. Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher) 2. Difficulty breathing 3. Cough 4. Sore throat 5. New or recent loss of taste or smell 6. Nausea, vomiting or diarrhea * Close contact with anyone who tested positive for SARS-CoV-2 infection within 28 days prior to screening or check-in (Day -1) * Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for males and 470 msec for females * Subjects who have any of the following abnormalities on laboratory values at screening or Check-In including: 1. White blood cell count \< 3,000/mm3, hemoglobin \< 11g/dL 2. Absolute neutrophil count ≤ 2,000/mm3, platelet count \<120,000/mm3 3. alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) greater than the upper limit of normal (ULN) for the reference laboratory * History of substance abuse or alcohol abuse * Use of prescription medicine \& tobacco/nicotine or marijuana-containing products * A female who is pregnant or breastfeeding * Other exclusion criteria per protocol